AppBlogHilfeonvista bank
Werbung ausblenden

News zu LYSOGENE S.A.(PROM.)-,30

Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA · Uhr · Business Wire
Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101 Presented at the WORLDSymposium™ 2022 · Uhr · Business Wire
Lysogene Provides Medical Update · Uhr · Business Wire
Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights · Uhr · Business Wire
Half-Year Report on the Liquidity Contract Signed by Lysogene with Kepler Cheuvreux · Uhr · Business Wire
Lysogene Awarded Innovation Passport by the UK MHRA for the GM1 Gangliosidosis Program · Uhr · Business Wire
Lysogene Secures a €4.3 Million Non-dilutive Financing From Bpifrance to Support Its Development · Uhr · Business Wire
Lysogene Announces a Presentation of its LYS-GM101 Program at the ESGCT 2021 · Uhr · Business Wire
Werbung ausblenden